NOVN.SW vs. ^GSPC

Last updated Apr 2, 2026

Compare and contrast key facts about Novartis AG (NOVN.SW) and S&P 500 Index (^GSPC).

Performance

NOVN.SW vs. ^GSPC - Performance Comparison

The chart below illustrates the hypothetical performance of a CHF 10,000 investment in Novartis AG (NOVN.SW) and S&P 500 Index (^GSPC). The values are adjusted to include any dividend payments, if applicable.

NOVN.SW vs. ^GSPC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NOVN.SW Novartis AG	15.55%	27.98%	8.44%	11.93%	8.75%	-0.11%	-5.39%	28.50%	6.51%	16.04%
^GSPC S&P 500 Index	-3.64%	1.70%	33.03%	13.11%	-18.34%	30.63%	6.46%	26.69%	-5.33%	14.35%

Different Trading Currencies

NOVN.SW is traded in CHF, while ^GSPC is traded in USD. To make them comparable, the ^GSPC values have been converted to CHF using the latest available exchange rates.

Returns By Period

In the year-to-date period, NOVN.SW achieves a 15.55% return, which is significantly higher than ^GSPC's -3.64% return. Over the past 10 years, NOVN.SW has outperformed ^GSPC with an annualized return of 12.23%, while ^GSPC has yielded a comparatively lower 10.18% annualized return.

NOVN.SW

• 1D: 1.69%
• 1M: -2.55%
• YTD: 15.55%
• 6M: 21.75%
• 1Y: 28.67%
• 3Y*: 19.68%
• 5Y*: 14.07%
• 10Y*: 12.23%

^GSPC

• 1D: 0.30%
• 1M: -2.38%
• YTD: -3.64%
• 6M: -2.18%
• 1Y: 5.12%
• 3Y*: 11.64%
• 5Y*: 6.69%
• 10Y*: 10.18%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NOVN.SW vs. ^GSPC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NOVN.SW

NOVN.SW Risk / Return Rank: 77
NOVN.SW Sharpe Ratio Rank: 82
NOVN.SW Sortino Ratio Rank: 73
NOVN.SW Omega Ratio Rank: 77
NOVN.SW Calmar Ratio Rank: 74
NOVN.SW Martin Ratio Rank: 82

^GSPC

^GSPC Risk / Return Rank: 67
^GSPC Sharpe Ratio Rank: 63
^GSPC Sortino Ratio Rank: 64
^GSPC Omega Ratio Rank: 69
^GSPC Calmar Ratio Rank: 60
^GSPC Martin Ratio Rank: 77

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NOVN.SW vs. ^GSPC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NOVN.SW) and S&P 500 Index (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NOVN.SW	^GSPC	Difference
Sharpe ratio Return per unit of total volatility	1.41	0.22	+1.19
Sortino ratio Return per unit of downside risk	1.78	0.47	+1.31
Omega ratio Gain probability vs. loss probability	1.27	1.07	+0.19
Calmar ratio Return relative to maximum drawdown	1.82	0.33	+1.49
Martin ratio Return relative to average drawdown	6.59	1.25	+5.34
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NOVN.SW vs. ^GSPC - Sharpe Ratio Comparison

The current NOVN.SW Sharpe Ratio is 1.41, which is higher than the ^GSPC Sharpe Ratio of 0.22. The chart below compares the historical Sharpe Ratios of NOVN.SW and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NOVN.SW	^GSPC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.41	0.22	+1.19
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.81	0.37	+0.44
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.68	0.52	+0.16
Sharpe Ratio (All Time) Calculated using the full available price history	0.50	0.25	+0.25

Correlation

The correlation between NOVN.SW and ^GSPC is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Drawdowns

NOVN.SW vs. ^GSPC - Drawdown Comparison

The maximum NOVN.SW drawdown since its inception was -42.25%, smaller than the maximum ^GSPC drawdown of -58.86%. Use the drawdown chart below to compare losses from any high point for NOVN.SW and ^GSPC.

Drawdown Indicators

	NOVN.SW	^GSPC	Difference
Max Drawdown Largest peak-to-trough decline	-42.25%	-56.78%	+14.53%
Max Drawdown (1Y) Largest decline over 1 year	-14.74%	-12.14%	-2.60%
Max Drawdown (5Y) Largest decline over 5 years	-16.86%	-25.43%	+8.57%
Max Drawdown (10Y) Largest decline over 10 years	-24.11%	-33.92%	+9.81%
Current Drawdown Current decline from peak	-2.96%	-5.78%	+2.82%
Average Drawdown Average peak-to-trough decline	-11.42%	-10.75%	-0.67%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.38%	2.60%	+1.78%

Volatility

NOVN.SW vs. ^GSPC - Volatility Comparison

Novartis AG (NOVN.SW) has a higher volatility of 5.59% compared to S&P 500 Index (^GSPC) at 5.00%. This indicates that NOVN.SW's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NOVN.SW	^GSPC	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.59%	5.00%	+0.59%
Volatility (6M) Calculated over the trailing 6-month period	13.35%	11.14%	+2.21%
Volatility (1Y) Calculated over the trailing 1-year period	20.57%	23.14%	-2.57%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	17.53%	18.21%	-0.68%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.16%	19.62%	-1.46%